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The incidence of mesh-related infection after abdominal wall hernia repair is low, generally between 1
and 4%; however, worldwide, this corresponds to tens of thousands of difficult cases to treat annually.
Adopting best practices in prevention is one of the keys to reduce the incidence of mesh-related
infection. Once the infection is established, however, only a limited number of options are available
that provides an efficient and successful treatment outcome. Over the past few years, there has been a
tremendous amount of research dedicated to the functionalization of prosthetic meshes with antimi-
crobial properties, with some receiving regulatory approval and are currently available for clinical use. In
this context, it is important to review the clinical importance of mesh infection, its risk factors, pro-
phylaxis and pathogenicity. In addition, we give an overview of the main functionalization approaches
that have been applied on meshes to confer anti-bacterial protection, the respective benefits and limi-
tations, and finally some relevant future directions.
© 2018 Elsevier Ltd. All rights reserved.1. Introduction to mesh-associated infection after hernia
repair
Abdominal wall hernia is a common surgical problem affecting
patient populations across the world. The main causes of abdom-
inal wall hernia are related to collagen disorders and/or insufficient
suture closing techniques after laparotomies (called incisional
hernia). The surgical repair of abdominal wall hernia, involves
repositioning the contents of the hernia sac (protruded organs) into
the abdominal cavity, and consequently the closure and rein-
forcement of the defect using either a suture (known as hernior-
rhaphy) or a net-like prosthesis (called mesh, known as
hernioplasty). The utilization of mesh materials over the last five
decades has brought clear advantages compared to direct suturing,
which was the previous standard protocol. Indeed, the meshg (O. Guillaume).approach is generally associated with reduced recurrence rates, a
quicker recovery, and lower risk of post-operative chronic pain [1].
Nevertheless, hernia repair using either suture or mesh tech-
nique can result in infectious complications [1,2], with incidence
rates between 1 and 4% of all patients. Hernia mesh-related infec-
tion is “a surgical disaster” [3], with dramatic effects for the patients
and incurs significant healthcare costs. Considering that more than
1 million hernia repair operations using mesh are performed
annually in the USA, it is estimated that approximately 60 000
inguinal and ventral hernia (corresponding to protrusion through
the inguinal canal or through the muscles of the abdominal wall
respectively) repairs become infected annually, with similar
numbers in Europe [4].
In the 2004 publication entitled “Post mesh herniorrhaphy
infection control: Are we doing all we can?” [5], Pr. Deysine sug-
gested that philosophical changes must be considered since sur-
gical site infection (SSI) in herniatology was still unacceptably high.
He compared the situation to the orthopaedic community, who
achieved a tremendous reduction of SSI within the last decades (e.g.
O. Guillaume et al. / Biomaterials 167 (2018) 15e3116by using filtered incoming air in theatres, local antibiotherapy,
three pairs of gloves, etc.) [5]. Among the possible routes for
progress, judicious surgical approaches but also technologies and
innovative techniques dedicated to the prevention of mesh infec-
tion are seen to play crucial role; and have already brought
promises in this challenging field [5]. As illustrated Fig. 1, the hernia
community is showing increasing interest in this field, with a
continuous augmentation of published reports dealing with mesh-
related infection and innovative strategies aiming to prevent hernia
surgical site infection (SSI).
In order to facilitate the development of innovative strategies
dedicated to tackle mesh related infection, we need to fully
comprehend the clinical problem. Therefore, the following review
will focus on biomaterials strategies used to fight against infection,
but will also include the pathogenesis of mesh-related infection,
the clinical solutions currently available and the recent advances in
anti-infective meshes.
2. Surgical site infection in herniatology
The Centers for Disease Control (CDC) in the US distinguishes
between incisional surgical site infections (SSI) occurring superfi-
cially and deeper within the body. By definition, a superficial inci-
sional SSI is an infection involving only the skin or subcutaneous
tissues, requiring relatively simple treatment based on wound
drainage accompanied by antibiotics administered systematically.
Mesh-related infection occurring after hernia surgery is, in
contrast, considered a deep incisional SSI, and more elaborate
treatment protocols may be required. In addition, because themesh
is considered an implant, the duration of surveillance and diagnosis
is extended to 1 year post-operatively (instead of only 30 days for
superficial SSI not involving implants), and it involves deep soft
tissues (e.g. fascia and muscle layers) [6,7].
2.1. Pathogenesis of mesh-related contamination
There are a small number of cases reporting non-sterile, coun-
terfeit meshes [8] or inappropriately re-sterilized meshes resulting
in sepsis and post-operative mesh infection [9]. Those clinical cases
are relatively rare, and, in fact, the main origin of microorganisms
remain the patient's skin or mucosa and the surgical environment
(e.g. flora of the caregiver) [2]. Generally, contamination is believed
to occur at the moment of the surgical insertion of the biomaterial
prosthesis into the abdominal cavity, caused by a small number of
adhering microorganisms.
Staphylococcus aureus and S. epidermidis are the leading causa-
tive microorganisms, responsible for approximately 90% of mesh-
related infection, with Methicillin-resistant Staphylococcus aureusFig. 1. Increasing awareness of mesh-related infections is reflected by the steady increase in
"isi web of knowledge" with key words "Mesh" þ "Hernia" þ "Infection".(MRSA) [10], responsible for up to 63% of mesh-related SSI [11,12])
[13]. Other bacteria have been isolated from infected meshes,
including Gram-positive species such as Streptococcus pyogenes [14]
and Enterococcus faecalis [15,16] and Gram-negative species such as
Pseudomonas sp. [14] and Enterobacteriaceae (such as Escherichia
coli and Klebsiella pneumonia [17,18]). Additionally, some reports
describe infection by other microorganisms such as Propionibacte-
rium acnes, mycoplasma, rapidly growing mycobacteria and
Candida albicans [19e21].
A critically important point to highlight is that biofilms formed
on medical devices are usually composed of several bacterial
strains, and mesh-related infections can also involve polymicrobial
infection [16,22]. In those complicated cases, the isolation, culti-
vation and identification of every causative agents still remains
challenging and numerous pathogens may remain underestimated
depending of the exact practices in the clinical microbiology lab
[16,23]. The utilization of modern biotechnological tools such as
gene sequencing has been recently employed as alternative to
conventional cultivation methods to analyse the microbial popu-
lation of explanted mesh following hernia recurrence [24]. The
authors of this work have demonstrated for the first time that
hernia meshes could be reached by bacteria, not only originating
from the skin and the gut of the patient, but also from oral site (due
to periodontal diseases) [24]. This study suggests as well that
bacterial biofilm settled on the meshes in patients without clinical
signs of infection could a priori also promote recurrence [24].
2.2. Incidence of SSI in herniatology
It is known that the insertion of a medical device increases the
susceptibility of infection by a factor 10 000 up to 100 000 [25]. In
the field of hernia repair, bacterial contamination occurs in 1/3
[19,26] up to 2/3 [24] of the implanted meshes either during mesh
insertion or even after years of implantation in cases where healing
is disturbed. Of those meshes colonized by microorganisms, rela-
tively few will develop infection with clinical symptoms of SSI, but
this risk persists for many decades after the surgical procedure [10].
Conventionally, the incidence of SSI in hernia surgery ranges be-
tween 1 and 4% in most of the literature reported over the last
decades [5], but it depends on numerous factors. Among the risk
factors of SSI, the nature of the hernia has been relatively well
documented. For instance, SSI incidence is around 2e4% in open
surgery for inguinal repair, but reach 6e10% in case of incisional
hernia operations [27]. The surgical approach has also a direct in-
fluence on SSI, e.g. using laparoscopic route is usually correlated
with lower SSI (compared to open surgeries) as it corresponds to a
minimal invasive act, with no need of large dissection [28]. With
the laparoscopic approach, SSI has be reduced to as lowas 0.1% [29].scientific reports published every year. Search was done on the 8th of August 2017 on
O. Guillaume et al. / Biomaterials 167 (2018) 15e31 17The experience and learning curve of the surgeons performing
the mesh implantation has also a tremendous impact on compli-
cations related to sepsis. Indeed, resident surgeons (non-expert in
the field of hernia repair) require more time to perform the pro-
cedure, which directly impacts the risk of SSI [15,30e32]. Other
important factors include the size of the implanted mesh (higher
risk if mesh surface is above 300 cm2) [15,32], its architecture
(higher risk when multifilament or dense membrane (such as
expanded form of polytetrafluoroethylene (ePTFE) compared to
porous monofilament structures) [15,19,28,33,34] or the presence
of drainage placed intra-operatively in order to prevent the accu-
mulation of fluid when placed for more than 3 days [35]. Patient
demographics also influences the risk of developing mesh infec-
tion, as for other surgical fields, including smoking [12,36,37], ex-
istence of chronic pulmonary disease [31] or diabetes [38], along
with patient age [12] and obesity [14,15].
However, those numbers do not necessarily and systematically
represent the reality, and in some cases underestimate the true
impact. Indeed, when a strict follow-up is performed, SSI rises well
above 5% [39] up to 14% [40]. Bailey stressed in 1991 that, from an
“acceptable” 7% of wound complication rates following hernia
repair (including 3% of SSI), in reality, for the same patients un-
dergoing rigorous postoperative surveillance, a 30% complication
rates including 9% of infection was reported. Finally, he concluded
that "complication rates are a reflection not only of the standards of
surgical practice but also the rigour with which they are sought" [41].3. Management of mesh-related infections
Generally, early wound SSIs (occurring within 30 days) are
relatively easy to identify, with patients presenting symptoms
characteristic of infection or inflammation, such as fever, focal
tenderness, erythema or swelling [7]. However, late mesh infection
can be indolent and more difficult to diagnose [42]. Clinically, the
diagnosis of deep abdominal wall infection involvingmeshmaterial
relies on the localization of peri-prosthetic inflammation with ab-
scess or fistula using radiological imaging techniques, such as ul-
trasound, computerized tomography (Fig. 2) or less frequently MRI.
Etiologic diagnosis is one of the cornerstones in themanagement of
the patient with SSI. Without such diagnosis, treatment of the pa-
tient is empirical, and the risks of unsatisfying outcome increase.
Those diagnoses are still based on classical methods, including a)
stain and culture of aspirated fluid, b) periprosthetic tissue cultures
or c) culture of liquid from sonication or agitation with vortex ofFig. 2. Clinical diagnosis and evolution of mesh-related SSI using Computed-tomography t
CT illustration of peri-prosthetic fluid accumulation due to mesh contamination (by MRSA
pointed out by the yellow arrow). Successful SSI eradication was reported after IV therapy
(three times daily for 4 weeks) added to a daily tablet of doxycycline for 12 months. The foll
the hernia (B). Reprinted with permission [18].totally or partially removed mesh.
Nevertheless, there are still numerous patients which have
negative microbiological results, despite symptoms of infection. In
consequence, improving the molecular biology tools for diagnosis
is another requirement for better management of these compli-
cated cases. In our opinion, it is crucial to further develop biomol-
ecular techniques that will allow the detection and identification of
the microorganisms present in a dormant state within mesh bio-
film. Novel methodologies such as fluorescence in situ hybridiza-
tion (FISH [16]) and gene sequencing [24] have already shown great
potential in diagnosis, which might help to understand the path-
ogenicity of mesh-related infection and better tune a more “indi-
vidualized” therapeutic approach.3.1. Strategies for mesh prophylaxis
Prophylactic administration of antibiotics, either systematically
or topically, is routine in some clinics, even if the real benefit in
terms of protection against mesh-related infection is still contro-
versial. Some authors do document a significant decrease in mesh
infection when antibiotics are administered pre-operatively. For
instance, in a prospective study of 280 patients hospitalized for
prosthetic hernia repair who received either placebo (saline solu-
tion) or 1.5 g of ampicillin-sulbactam, Yerdel et al. registered an
astoundingþ/-10-fold reduction in wound infection rates (from 9%
to 0.7%), including a 3-fold decrease in deep SSI (from 2.2% to 0.7%)
in the respective groups [39]. This decreased SSI had a direct impact
on hospitalization duration, from 1.2 days when no complication
occurred, up to 12 days in the cases of infected meshes. Similarly,
reports tend to demonstrate as well that pre-operative adminis-
tration of antibiotics may be helpful in institutions experiencing
high rates of infection (>5%) [43] and where non-expert residents
are performing the surgeries, along with high risk patients.
Nevertheless, as summarized by Erdas et al., “Currently, there are no
convincing arguments for recommending the routine use of antibiotic
prophylaxis for groin hernia repair, especially in clinical settings with
low incidence of SSI” [30].
Prophylactic administration of antibiotic relies generally in
bolus injection, performed usually 30min before starting the sur-
gical procedure [30]. Alternatives to systemic administration of
antimicrobial drugs have been proposed, using local approaches
[44] by delivering antibiotics directly to the surgical wound. An
early report from 1980 failed to demonstrate efficacy of local
deposition (1 g of ampicillin as powder) on the incidence of herniaechnique.
) 2 weeks post-operatively (A, abdominal wall is denoted by red stars and seroma is
with vancomycin (for 2 weeks) followed by local irrigation with gentamicin solution
ow-up scan at 1 year demonstrated absence of fluid, signs of infection, or recurrence of
O. Guillaume et al. / Biomaterials 167 (2018) 15e3118repair infection (SSI rate of 3.7% versus 4% for placebo) [45]. Using
another antibiotic, Lazorthes et al. published a decade later com-
plete prevention of SSI in patients receiving locally 750mg of
cefamanadole [46], compared to a 4.3% incidence of SSI for placebo
group (p¼ 0.007, on 162 patients/group). In another study, wound
irrigation with gentamicin (80mg) along with IV antibiotherapy
(1 g of Cefazolin) cleared all risk of mesh-related hernia infection
for more than 25 years of utilization [47].
Looking at other surgical fields, e.g. orthopaedic surgery where
the utilization of local drug delivery systems in combination with
systemic therapy is common [48], Musella et al. significantly
reduced the occurrence of mesh infection when collagen sponges
impregnated with gentamicin were inserted in front of the pros-
thesis before suturing the wound (rate of SSI of 0.3% vs 2%, on 594
patients) [49]. Surprisingly, the utilization of such devices in her-
nioplasty is the exception and a limited number of reports is
available in the literature to clearly estimate the benefit (refer to
section 7).
3.2. Treatment of established infections of hernia implants
According to a recent issue from General Surgery: “Total ex-
penses associated with a mesh infection came to $107,000 […]. In
comparison, a patient without hernia repair complications will incur
hospital costs of $38,700 and an additional $1400 in follow-up charges
over the next 12 months” [50]. This has to be added to the fact that
hernia repair is the most common operation in general surgeries
(with rate ranging for 10 per 100 000 persons in UK up to 28 per
100 000 in US, all ages included [51]), resulting in approximately
60 000 mesh infections in US only [52,53].
The gravity and the treatment of infection following mesh im-
plantation differs depending on the localization of the contami-
nation. In hernioplasty, superficial SSI requires relatively simple
treatment based on wound drainage and systemic antibiotic ther-
apy. In contrast, the deep SSI of the implanted graft is much moreFig. 3. Treatments of established mesh-related infection in herniatology.
Illustration of ventral hernia infected mesh with high degree of tissue erosion and mesh ext
closure) used to drain peri-prosthetic infectious fluid. Excision of the non-integrated porti
reprinted with permission from Ref. [2]).serious and can even be fatal for the patient (mortality rate of 1.1%
in hernioplasty of complicated clinical cases [54]).
After diagnosis of mesh infection, surgeons have either the
choice of a conservative management with retention of the mate-
rial, or its removal.
Whenever possible, a conservative approach with mesh salva-
tion is preferred as it is less invasive for the patient than mesh
removal, and it decreases the risk of re-herniation [37]. Following
the diagnosis of infection, the basic treatment includes seroma
extraction and the area is washed and disinfected using an
antibiotic-containing irrigation (i.e. gentamicin solution) [18]. Pa-
tients will generally be treated with IV antibiotics initially followed
by oral antibiotics for up to 12 weeks [37]. Despite these efforts, the
long-term success rate is relatively limited and, frequently, the
same patients can encounter recurrence of infection, which will
eventually require the removal of the infected mesh [55]. In fact,
the success of mesh conservation depends on the nature of the
prosthesis, and salvation is relatively more efficient on mono-
filament mesh than on multifilament meshes or on dense PTFE or
its expanded format patches (ePTFE) [56]. SSI occurring in mono-
filament mesh do not usually require the explantation of the ma-
terial [15,57], which correlates with in vitro experiments revealing
that bacteria persist better on multifilament meshes [58].
A multistage reconstruction approach is more often successful
in treating contaminatedmeshes (Fig. 3). This method relies first on
the debridement of necrotic tissues and excision of the infected
materials (Fig. 3C and D), followed by routine irrigation with anti-
biotics and temporary closure with vacuum-assisted closure (VAC®,
illustrated Fig. 3B) [15]. Additionally, patients are treated with IV
antibiotic therapy for few days until the symptoms of infection
subside and, only at this point, a definitive closure of the wound
with a newmesh material can be attempted [59]. Such a multistage
approach can be relatively tedious for the patient as a clean wound
situation must be achieved before the final closure, which can take
few days to few weeks [60].rusion (A, reprinted from Ref. [17]) and application of VAC® system (B, vacuum assisted
on of infected mesh, defined after local injection of methylene blue dye (B, C and D,
Fig. 4. Influence of mesh topography on susceptibility to infection.
S. aureus adhesion in vitro was shown to be higher on multifilament meshes (A, SEM illustrations B and C, reprinted with permission from Refs. [58,76]). Bioluminescence signal
follow-up of mesh infection on mice over 10 days on mono-versus multifilament meshes (radiance intensity correlates with degree of infection), reprinted with permission from
Ref. [74].
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more frequently in patients treatedwith ePTFE, as this patch cannot
be drained efficiently due to its dense and laminated architecture
[56]. Importantly, implanting biologic graft in dirty or contami-
nated environment is not advocated anymore as no study has
clearly demonstrated superiority compared to macroporous syn-
thetic meshes [61e65].
Despite such tedious protocol, mesh removal results in high risk
of hernia recurrence (up to 20% [17]) and some patients need up to
five re-operations for the healing to take place [42,66].
To conclude, mesh infection is not the most frequent compli-
cation occurring after mesh hernioplasty; however it does remain
critical for the patients and for the healthcare systems. From this
perspective, it is clear that there is substantial need for innovative
solutions that could tackle mesh contamination.
4. Advances in antibacterial meshes
In order to decrease the risk of developing an infection, a sig-
nificant amount of work has been done focusing on the function-
alization of the prostheses to exhibit anti-infective behaviour.
Those strategies can be basically categorized as passive (i.e. opti-
mizing mesh design and macro-/micro-architecture) or active
(combining therapeutics to the mesh materials) systems.
4.1. Guidance based on selection of appropriate mesh composition
The first strategy aiming to prevent mesh infection lies in the
selection of appropriate prostheses, which is not as straight for-
ward as we could think due to wide choice of meshes available in
the market (more than 200 different commercialized meshes only
in USA [67]). Those meshes are all characterized by specific struc-
ture, porosity, composition, weight, etc., which complicates the
final decision for the surgeons [68].
Klinge et al. were among the first to investigate and compare
how the morphological properties of different commercial meshes
influence their susceptibility of infection [58]. They demonstrated
that under in vitro condition, the ability of S. aureus to adhere to thematerials was approximately 2-times reduced using monofilament
mesh compared to multifilament (Fig. 4A, B and C). This was sup-
posedly related to the increased surface area of the multifilament
prostheses (of a factor 1.57 compared to monofilament meshes)
alongwith the presence of microscopic additional niches, favouring
bacteria attachment and biofilm settlement [69]. However, this
hypothesis was not validated in their subsequent rat study, on
which both groups showed similar degree of infection [58]. Further
in vitro investigations undertaken by Bellon et al. have shown that,
on polypropylene (PP) monofilament meshes bacteria grow pref-
erentially at the node or filament crossover regions, whereas on
ePTFE patches, they adhere between the internodal filaments [70].
Infected meshes do not seem to have altered mechanical proper-
ties, but the presence of microorganisms does impair the quality of
integration in the host tissue [71e73].
More recently, different commercially available meshes were
screened under in vivo condition (using infected rodent models)
and authors observed a higher rate of bacteria clearance in
monofilament compared to multifilament (Fig. 4D) [74], to com-
posites and to laminate patches [75]. The available data on this
topic indicates that such observations are true for synthetic meshes
made of both permanent [69,74] and biodegradable polymers [73].
Mesh architecture in terms of weight and diameter of porosity
were also shown to impact biomaterials susceptibility to infection
in a rabbit infected model, favouring very large porosity
(3.6mm 2.8mm) and light weight (48 g/m2) knitted meshes [34].
The material composition of the meshes is another important
factor to be taken into consideration regarding SSI. As already
mentioned, biological grafts have been introduced in the past as
suitable alternative to synthetic meshes in an infected environ-
ment. However, this is no longer considered best practice due to a
number of adverse findings. Indeed, biological grafts are prone to
higher bacteria adhesion compared to synthetic meshes
[61,63,76,77] and graft infection can trigger premature in vivo
degradation [62,78] and poor neovascularization [61]. A recent
clinical study conducted on 73 patients with complex abdominal
wall reconstruction showed that degradable meshes made of syn-
thetic polymers (Phasix™ made of poly(4-Hydroxybutyrate) by
O. Guillaume et al. / Biomaterials 167 (2018) 15e3120Bard) are better able to resist infection, compared to biomeshes
(porcine cadaveric prosthesis by Lifecell), with occurrence rate of
12.9% versus 31% respectively [79].
To withstand biomesh deterioration due to the presence of
collagenase-forming bacteria, several cross-linkers have been used
to chemically stabilize the collagen compartment of such products
(glutaraldehyde or hexamethylene diisocyanate) [63], but without
any clear clinical benefits.
Such recent reports continue to foster criticisms regarding the
utilization of biological implants in contaminated hernia [64],
which is associated with their excessive cost (a 25  40 cm biologic
prosthesis costs þ/ $32 000) compared to synthetic poly-
propylene mesh (equivalent to $150) [80].
4.2. Utilization of meshes as drug delivery systems
4.2.1. Delivering antibiotics
The first attempt to add antibiotics to hernia meshes was re-
ported in 1999 by Goeau-Brissoniere using simple immersion
technique [81]. The rationale behind this approach was that local
delivery of antibiotics maximizes specific tissue concentration and
minimizes systemic toxicity. Using the implant as carrier for
delivering drugs and improving therapeutical efficacy is a common
strategy in some surgical fields, such as in orthopaedic surgery and
has significantly helped reducing SSI [48,82]. This trend has not yet
reached the field of soft tissue repair as a routine practice. Never-
theless, numerous reports have shown promising outcomes in vitro
and in animal models, summarized in Table 1. Among the listed
antibiotic agents, aminoglycoside (e.g. gentamicin) or glycopeptide
(e.g. vancomycin) are the most common drugs delivered in com-
bination with meshes.
Gentamicin has a broad spectrum of activity (against both
Gramþ and Gram-microorganisms) and is one of the most potent
antibiotics against staphylococcal infection [83]. In the 2005 review
“Mesh-related infections after hernia repair surgery”, Falagas was
one of the first to hypothesise that embedding antibiotics directly
with meshes could help in reducing bacterial adhesion and colo-
nization [38]. The same year, pioneer report on mesh functionali-
zation using antibiotics was published by Junge et al. using
gentamicin grafted on polyvinylidene fluoride (PVDF) [84]. The
authors reported a significant mesh protection against S. aureus for
24 h, but only under in vitro condition and this was unfortunately
never translated to an animal study.
A limitation of aminoglycosides is that they are known to in-
crease the risk of resistance among staphylococcal species. For
instance, on a total of 250 clinical isolates of S. aureus, a recent
investigation performed by Neeta et al. revealed a resistance rate
against gentamicin of 26.4% (56% for MRSA stains). Consequently, as
MRSA is responsible for a significant number of mesh-related in-
fections, prophylactic monotherapy based on gentamicin, but also
on fluoroquinolone, b-lactam (penicillin, cephalosporin, carbape-
nems) and even rifampin is not recommended.
Alternatively, vancomycin might be a better candidate and is
nowadays the drug of choice for treating most MRSA infections in
clinics, caused by multi-drug resistant strains. Vancomycin-loaded
meshes were reported by four different groups [85e87], with
complete bacteria clearance obtained in 3 out of 4 studies involving
infected animal models (on mice [86,87], rat [88] and rabbit model
[85]), requiring a loading charge of approximately 10 %w/w (eq. to
±0.30mg/cm2 of prosthesis). Using a higher vancomycin loading
(1.75mg/cm2) on similar bioactive mesh allowed to clear infection
in an infected pig model [89].
Mesh coatings using amoxicillin or ofloxacin could also protect
the meshes from E. coli contamination in a rat model [90], but no
solid data proves the same efficacy on staphylococcal infections(other than in vitro results presented by Laurent et al. [91]) and
MRSA are commonly resistant to such antibacterial agents [92].
In order to enlarge the spectrum of activity of the antibacterial
meshes, and to decrease risk of resistance, one strategy is to
combine antibiotics using multi-therapy. This is particularly true
for rifampicin, which is a potent staphylococcal drug (active against
MRSA) able to penetrate biofilm, but resistance develops quickly
during long-term treatment, and should always be used in com-
bination with other antibiotics. For instance, combining rifampicin
with a fluoroquinolone in a dual-coating allowed the in vitro inhi-
bition of a large panel of microorganisms and to significantly
decrease biofilm formation on PP meshes (Fig. 5B and C) [93]. In a
rabbit model, bioprostheses impregnated with rifampicin and
minocycline resulted in a complete prevention of MRSA and E. coli
infection [94]. Such dual-therapy, including one bactericidal and
one bacteriostatic agent, is highly efficient against both Gram-
positive and Gram-negative bacteria (Fig. 5 A).
Even though lots of studies have demonstrated substantial ef-
ficacy under in vitro condition, very few have been able to
completely protect the graft from contamination in infected animal
models.
4.2.2. Delivering antiseptics
The misuse of antibiotics in prophylaxis promotes the occur-
rence of resistance and results in difficult situation for the clinicians
hoping to treat patients suffering of SSI. Alternatives, including the
local administration of antiseptics, have become more a more
commonly observed approach to prevent such complications.
Along with antibiotic-loaded meshes, antiseptics have also been
combined with prosthetic materials for hernia repair (Table 2). We
found the record of two animal studies using dual-antiseptic stra-
tegies to prevent S. aureus infection, but with somewhat limited
performance (only partial diminution of bacteria loading)
[102,103]. Antiseptics have the great advantage of a broad spectrum
of efficacy and rarely trigger resistance. Among antiseptics, triclo-
san has been used in clinics since more than 30 years (under the
form of surgical scrubs, handwashes, dental hygiene solution, etc.).
Sutures coatedwith triclosan are commercially available since 2003
(trademark VICRYL® Plus Antibacterial, from Ethicon) and has
recently been approved as a recommendation by the World Health
Organization to address a key risk factor for infection, indepen-
dently of the type of surgery [104]. By using similar approach,
polypropylene meshes were functionalized with a biodegradable
adhesive chitosan gel embedding triclosan drug. In vitro, the
diffusion of triclosan was relatively fast (80e90% was released
within 24 h), which allows, in an infected in vivo model, to reduce
partially S. aureus mesh infection after 8 days [102].
4.2.3. Delivering metallic antimicrobials
Doping medical devices using silver coating or silver nano-
particles (AgNPs) is a frequent strategy to confer protection against
microorganisms (Table 3). AgNPs have a high potential to solve the
problem of multidrug-resistant bacteria because microorganisms
are unlikely to develop resistance against silver as compared with
antibiotics. However, it is important to note that only silver in its
soluble form (i.e. Agþ) exhibits biological activity, which is directly
related to the concentration, the size, the shape and the
morphology of the silver nano-particles [106]. Nanotechnology has
been of tremendous impact in the field of antimicrobial silver-
based therapeutics, as it is now possible to control and stan-
dardize the abovementioned nano-scale characteristics of the
AgNPs. The still hypothetical mechanisms of action rely in either
the alteration of cell membrane permeability or/and on the inhi-
bition of DNA replication. Interestingly, by blocking exopoly-
saccharide biosynthesis, silver can also disturb biofilm formation
Table 1
List of antibiotic-loaded meshes developed and main outcomes of the studies.
Therapeutical
agent
Technique of mesh
functionalization
Mesh substrate Amount loaded Model Micro-organisms
targeted
Main outcomes Ref.
Mono-therapy
Gentamicin Plasma activation of PVDF followed
by graft polymerization of polyacid
acrylic and covalent immobilization
of gentamicin
Polyvinylidene
fluoride
(PVDF)
45 mg/cm2 In vitro S. aureus
S. epidermidis
E. coli
S. aureus
Diameter of inhibition
ranged from 18.5 to 25.1
mma
More than 99.9% reduction
after 24 hrsb
[84]
[95]
impregnation Polyester
(PE)
PP with PGCL
membrane
1.68mg/cm2
0.24mg/cm2
In vitro 3 different
strains of
S. aureus
Complete bacteria
eradicationb
[96]
Gentamicin
Vancomycin
Rifampicin
impregnation gelatin-coated
PE mesh
0.10
0.10
0.21mg/cm2
In vivo
Rabbit model
S. aureus Complete bacteria
eradicationb
[81]
Vancomycin First chemical coating of cyclodextrin
and then incubation of antibiotic
PE 11.8 % wt In vivo
Mice model
S. aureus Complete bacteria
eradication
[86]
Idem PE 9 % wt In vivo
Mice model
S. aureus Complete
bacteria eradication
[87]
Idem PE 1.75mg/cm2 In vivo
Pig model
MRSA Complete bacteria
eradication
[89]
Dispersion of drug in
methacrylate-based matrix
used as coating by solvent
casting
PP 0.32mg/cm2 In vitro
In vivo
Rabbit model
S. aureus
S. epidermidis
Inhibition of bacteria
development for 14 daysa
Good tissue response and
limited inflammatory
reaction in treated group
(no bacteria detected)
[85]
Mesh soaking PE, PE with collagen
antiadhesive barrier,
PP and composite PP
with antiadhesive
membrane
From 0.04 up
to 2.1mg/cm2
In vivo
Rat model
MRSA Partial bacteria clearance
from 50 to 80%
[88]
Ciprofloxacin First chemical coating of cyclodextrin
and then incubation of antibiotic
PP 40mg/g In vitro S. aureus
S. epidermidis
E. coli
Significant bacteria
inhibition for 12e24 hrsa
[91]
Ampicillin Plasma treatment to load drug then
entrapment via PEG polymerization
PP 60 % wt In vitro S. aureus
E. coli
Addition of drug does not
improve S. aureus
inhibition (45mm2)a
but for E. coli 750mm2
[97]
Tetracyclin Drug incorporated in electrospun mat PLGA and PEUU
electrospun mat
up to 7.7 % wt In vitro
In vivo
Rat model
E. coli
Faecal
contaminant
Partial inhibition of bacteria
proliferation for 3 to 7 daysa
Limited wound dehiscence
[98]
Amoxicillin Drug dispersed in PLA50 solution
and casted on mesh
PP 0.67mg/cm2 In vitro
In vivo
Rat model
E. coli No viable bacteria
detectedb
No biofilm formation
No sign of infection and
negative culture
[90]
Ofloxacin 0.33mg/cm2
Ofloxacin Bi-layer coating of polyester
(PCL and PLA50) containing drug
PP 0 up to 1.1
mg/cm2
In vitro E. coli Significant inhibition of
bacteria proliferationa,b and
biofilm formation at
0.11mg/cm2
[99]
Cefalozin Infusion in mesh PGA-TMC 10mg/cm2 In vivo
Rat model
MRSA Partial decrease of bacteria
colonization
[100]
Bi-therapy
Ciprofloxacin
with chitosan
Oxidation of substrate followed by
coating deposition via foulard method
PP ±48 mg chitosan
and 4.3 mg
of drug
In vitro S. aureus Absence of CFU after 1, 2
and 7 daysb
[101]
Ofloxacin þ
rifampicin
Tri-layer coating of polyester
(PCL and PLA50) containing drugs
PP 0.11
mg/cm2
for each
In vitro E. coli,
S. aureus, S.
epidermidis,
MRSA,
Enterococcus
faecalis
P. aeruginosa
Klebsiella
pneumoniae
Large ZOI (for up to 72 h)
and absence of bacteria
colonizationa,b Drastic
diminution of Biofilm
formation
[93]
Minocyclin þ
rifampicin
Impregnation of drugs on
tyrosin-based matrix
Biomesh 115 mg/cm2
for each
In vitro
In vivo
Rabbit model
MRSA
E. coli
Large ZOI of
36 and 16mm
Limited acute inflammatory
response and total bacteria
clearance
[94]
In vitro assessments using either an aagar diffusion test or a bcolony counting (colony forming unit, CFU). ZOI: Zone of inhibition. Abbreviation: poliglecaprone (PGCL),
poly(lactic-co-glycolic acid) (PLGA), poly(etherurethane urea) (PEUU), poly(glycolic acidetrimethylene carbonate) (PGA-TMC).
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Fig. 5. Efficacy of multi-drug loaded hernia prostheses to clear bacteria in vitro.
Illustration of diameter of inhibition of bioprosthesis containing rifampin and minocycline (XenMatrix™ AB) on MRSA and E. coli 24 h post-inoculation compared to non-active
commercial grafts (A). Quantification of diameter of inhibition (B), anti-adherential and anti-biofilm activity (C) of PP mesh coated with rifampicin and ofloxacin (reprinted
with permission from Refs. [93,94]).
Table 2
List of antiseptic-loaded meshes developed and main outcomes of the studies.
Therapeutical agent Technique of mesh
functionalization
Mesh
substrate
Amount
loaded
Model Micro-organisms
targeted
Main outcomes Ref.
Chlorhexidine
versus chlorhexidine
þ allicin
Soaking PP Not reported In vitro
In vivo
Rabbit model
S. aureus ZOI of 36.9 and 25.7mm for
bi- compared to mono-therapya
Partial bacteria clearance,
but no advantage of combination
[103]
triclosan and chitosan Mesh embedded
in gel þ drug
PP Not reported In vivo
Rat model
S. aureus 3-log reduction of bacterial contamination [102]
a In vitro assessments using colony counting (colony forming unit, CFU). In Perez-Kohler et al. study [103], allicin was combined to chlorhexidine as previous report has
demonstrated that allicin (extracted from garlic) exerts antibacterial activity [105].
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100 nM of silver nanoparticles resulted in a decrease of 95% and
98% of the biofilm formed by P. aeruginosa and S. epidermidis
respectively [107]. Diverse substrates have been functionalized
using silver nanoparticles, as listed Table 3 and illustrated Fig. 6. For
instance, macroporous PP meshes coated with nano-Ag signifi-
cantly reduced in vitro E. coli proliferation (Fig. 6A, B and C) [108].
Another study reported the feasibility of agglomerating silver par-
ticles onto biological prosthesis by simple immersion, with a rela-
tively fine control of loading depending on the initial concentration
of the immersion baths (Fig. 6C, D and E) [78]. Experiments per-
formed on infected models have only shown partial protection of
meshes containing silver nanoparticles [78,108] and further results
are truly needed to positively appreciate such technology.
As an alternative to silver, Saygun et al. presented metallic
coating performed on PP mesh based on gold and gold-palladium
[109]. A 5 nm coating completely prevented in vivo mesh coloni-
zation by S. epidermidis for the alloy Au-Pd, whereas 30% and 100%of infection rates were registered for Au alone and for the control
mesh respectively. The anti-bacterial mechanism is not fully un-
derstood, but according to the author's point of view, it mainly
depends on the surface hydrophilicity, which was increased
following Au-Pd deposition over the hydrophobic PP mesh. This
explains why S. epidermidis, known to be hydrophobic, adhered
preferably on PP than on Au-Pd coated PP meshes. Nevertheless,
this preventive strategy might not be as efficient on other hydro-
philic bacteria, such as S. aureus.
4.2.4. Delivering antimicrobial peptides
Another class of antimicrobial arsenal that has been combined
with meshes are the antimicrobial peptides (AMPs) (Table 4). For
instance, lysostaphin is a potent antimicrobial agent against
staphylococcal strains (including S. aureus MRSA and
S. epidermidis). As endopeptidase, lysostaphin rapidly lyses bacteria
by creating microperforation, disrupting bacteria cell walls. Those
naturally occurring enzymes have the ability to penetrate biofilm
Table 3
List of metal-loaded meshes developed and main outcomes of the studies.
Therapeutical agent Technique of mesh
functionalization
Mesh substrate Amount loaded Model Micro-organisms
Targeted
Main outcomes Ref.
Gold and Gold-Palladium
(ratio 60/40)
Plasma deposition PP 0.05mg/cm2
Coating of 5 nm
In vitro
In vivo
Rat model
S. epidermidis Both coatings decreased
drastically mesh contamination
(after 6 h up to 72 h of
incubation)2
Complete prevention of
infection in Au-Pd. 30% of
infection for Au group.
[109]
Silver nanoparticle
(size of 11 nm)
Plasma polymerization of
PAA followed by physical
entrapment of nano-Ag
PET 1% w/w¼
1.4 mg/cm2
In vitro S. aureus
E. coli
Clear ZOI on both
microorganismsa
A 3 and 5 log10 reduction in
bacteria proliferation was
detected compared to control
meshb
[110]
Nanocristalline
silver coating
Physical Vapor Deposition PP 0.31/0.64/1.13
mg/cm2
In vitro S. aureus Direct relation between ZOI and
the silver loadinga
Complete eradication of
bacteria proliferation (decrease
of 8-log within 8 h)b
[53]
Silver nanoparticles
(size of 24 nm)
Not reported PP Not reported In vitro
In vivo
E. coli A 3 to 4-log reduction after 1 h
of adhesion assayb and absence
of biofilm formation
Prevention of infection in 70%
of the animals
[108]
Silver Immersion in AgNO3
solution
Polyurethane
nanofibrous mat
Not reported In vitro S. aureus
E. coli
Partial diminution in bacteria
adhesionc
[111]
Silver nanoparticles
(size 15 nm)
Immersion in solution of
silver nanoparticles
Biological graft ±15 mg/cm2 In vitro
In vivo
Rat model
S. aureus
S. epidermidis
P. aeruginosa
E. coli
S. aureus
Large diameter of inhibition
(antibacterial activity against S.
aureus last up to 2wks)a
Partial protection: Incidence of
SSI is 14% in silver group versus
38.8% in control
[78]
In vitro assessments using either.
a Agar diffusion test.
b Colony counting (colony forming unit, CFU) or.
c SEM observation. ZOI: Zone of inhibition.
Fig. 6. Silver coating strategies employed on synthetic or biological prostheses to reduce susceptibility to infection.
Microscopic illustration of macroporous monofilament PP meshes coated with 24 nm silver nanoparticles embedded in a gel (A and B), allowing to significantly decrease in vitro
mesh colonization by E. coli (compared to uncoated PP mesh, C). Silver nanoparticles can also be dispersed onto Porcine Small Intestinal Submucosa (PSIS, D and E), by simple
immersion technique which permits to easily control the amount of loaded Ag depending on the silver concentration in the bath (F). Reprinted with permission from Refs. [78,108].
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Staphylococcus sp. Based on literature, minimum inhibitory con-
centration MIC 90 of lysostaphin against S. aureus ranged from
0.001 to 0.064 mg/mL, which is much lower than other potent
antibiotic alternatives (i.e. vancomycin is 2 mg/mL) [112]. Given that
S. aureus is causative microorganism responsible for around 90% ofmesh-related infections, such enzyme could be of tremendous in-
terest [112]. Preliminary in vivo experiments performed on mice
revealed that such systems are effective as treatment of established
infection or as prophylaxis tool [113]. Another positive point is that
lysostaphin does not have a direct effect on eukaryote cells and
exhibits low toxicity [114,115]. Several investigations reported the
Table 4
List of antimicrobial peptides combined with meshes and main outcomes of the studies.
Therapeutical
agent
Technique of mesh
functionalization
Mesh
substrate
Amount
loaded
Model Micro-organisms
targeted
Main outcomes Ref.
Enzymes Lysozymes Non-specific adsorption
Non-specific adsorption
Chemical immobilization
(Sulfo-SAND)
PP Not
reported
In vitro S. aureus 100% survival rate [116]
Lysostaphin
(Staphylococcal
endopeptidase)
25% survival rate
98% survival rate
Lysostaphin Non-specific adsorption Biomesh 12 mg/cm2 In vivo
Rat model
S. aureus Complete bacterial
eradication
High rate of death of
sepsis in non-lysostaphin
groups
[117,118]
Non-specific adsorption PP and PE up to
30 mg/cm2
In vivo
Rat model
S. aureus Complete eradication
using 30 mg/cm2
[112]
Polyclonal
antibodies
Human IgG CMC-IgG gel applied
on mesh
PP 10mg/cm2 In vivo
Mice model
MRSA
P. aeruginosa
0% survival rate
70% survival rate
[120]
AMPs Human beta defensin
(HBD-3)
Non-specific adsorption
Compared to covalent
immobilization
PP Not
reported
In vitro S. aureus 100% survival rate [116]
Human
cathelicidin (LL-37)
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[112,116e118] and demonstrated a significant antibacterial pro-
tection under in vitro [116] and in vivo condition [117,118], higher
than other AMPs (i.e. HDB and LL-37 [116]), listed Table 4. However,
mutant strains losing the peptidoglycan enzymatic targets (gene
encoding for femA protein) is reported inducing a complete resis-
tance against such AMPs [119].
As alternative to staphyloccocus-specific lysostaphin, other non-
specific enzymes have been briefly tested in this field, such as ly-
sozymes [116]. The advantage is their larger spectra of activity
compared to lysostaphin, as lysozymes target as well the cells wall
of Gram-positive bacteria, impairing or lysing bacteria cell mem-
brane [121]. Nevertheless, the only report on lysozyme-
impregnated meshes did not support their further development
[116] (Table 4).
Another option is to prolong the levels of protective immuno-
globulin, which is naturally secreted during any surgical proced-
ures. To do so, researchers have proposed to locally deliver IgG
directly from the mesh (using a coating based on hydrogel of
carboxymethylcellulose and pooled polyclonal human IgG) [120].
The rationale of this prophylactic treatment is to exacerbate the
phagocytosis of planktonic bacteria by adding exogenous opsonic
antibodies. Such approach has been successfully used in clinic since
several decades through IV administration in a number of disorders
[122]. In the presented IgG-delivery mesh, no beneficial effect was
reported on MRSA infected mice when employed as monotherapy
and showed only partial efficacy in implant-associated P. aeruginosa
contamination [120].5. Manufacturing technologies
Another important aspect to take into consideration in the
development of antimicrobial meshes relies on the available op-
tions which are offered for the manufacturing of such bioactive
implants. Several physical and chemical methodologies have been
reported to combine antimicrobial components to mesh substrates,
which will be presented in the next paragraphs.5.1. Dipping/soaking
The simplest way to combine therapeutics to any medical de-
vices is by immersion. The first attempt to combine mesh with
antibiotics was reported in 1999 by direct immersion in solutions ofeither gentamicin (10mg/mL), rifampicin (20mg/mL) or vanco-
mycin (10mg/mL). The loading efficiency was estimated to be
around 0.10e0.20mg/cm2 of prosthesis, which was sufficient to
prevent contamination in an infected rabbit model [81]. Non-
specific physical adsorption of antibiotics [81,88,96,100], antisep-
tics [103] and enzymes [112,116] were reported by dipping or
soaking aqueous solution containing the therapeutics directly on
the meshes. Under such condition, the amount of antibacterial
compound loaded depends mainly on the fluid adsorption capa-
bility of the mesh substrate. Wiegering et al. determined this
adsorption factor experimentally, which was equal to 3.8 for
multifilament meshes (polyesters) and only 2.1 for monofilament
meshes (polypropylene/poliglecaprone). Similar results were pre-
sented by Sadana et al., evaluating the antibiotic uptake for
different commercial meshes following incubation in vancomycin
solution at 10mg/mL for 15min, which ranged from 0.04mg/cm2
for polypropylene monofilament up to 2.1 for composite PP/
hydrogel prosthesis [88], with a direct impact on in vitro MRSA
clearing capability. This methodology has the advantage of being
realisable directly in the theatre by the surgical team before the
insertion of the mesh in the patient, and consequently should not
necessitate specific FDA-approval has themeshmaterial by it-self is
not modified. Presoaking meshes in antibiotic solution does not
lead to prolonged delivery, but aims principally in covering the
critical early postoperative period to prevent bacterial adhesion to
the materials, which was defined to be around 6 h [120]. A clinical
study has shown that almost no antibiotic was detectable in pa-
tient's serum 24 h following the implantation of gentamicin pre-
soaked meshes [96]. However, such technology has not yet
shown clinical superiority over systemic antibiotic therapies [27],
and further optimization should be sought to improve the thera-
peutic window and to prolong the duration of activity.5.2. Physical coating
In order to facilitate the loading of the prosthesis, to protect the
therapeutics, or to control the elution profile, degradable polymers
have been commonly employed as drug carriers through several
mesh coating technologies. Functionalization of mesh has been
proposed using a solvent casting methodology. Solvent casting is
either performed by drop-by-drop deposition of the coating agents
using a pipette onto the mesh [85,90,123] or by immersion of the
mesh in the mixture [102], before a final drying step. Alternatively,
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requiring the passage of the mesh between two rolls foulard pre-
impregnated with the antibiotic solution [101]. Several mesh
coatings, based on water soluble (chitosan [102] [101], or poly-
acrylic [85]), or organo-soluble (PLA50 [90]) biomaterials have been
presented using solvent casting technique. Such physical embed-
ding of antibiotics in polymeric matrices allows for sustained
release of drugs, from 7 days [90,101] up to one month [85]
(experimented under in vitro [90,101] or in vivo [85] conditions).
However, it remains relatively difficult to control the deposition
and the thickness of the formed peri-prosthetic layers and to pre-
serve the macroscopic porosity of the mesh substrate.
Taking example of previously described endo-prostheses
coating technology, Guillaume et al. employed an airbrush system
to deposit organic-based solution containing therapeutics com-
bined with polymeric carrier onto macroporous meshes [93,99]
(Fig. 7A). Compared to the aforementioned technologies, this
spraying technique is relatively versatile in terms of control of the
amount of materials to be deposited and allows for multiple
layering approaches. Indeed, three successive polymeric coating
layers were created surrounding the mesh (of a total thickness
ofþ/-20 mm), allowing for the dual sustained release of ofloxacin
and rifampicin. Advantageously, those techniques result only on a
physical coating surrounding the mesh (Fig. 7B and C), and do not
involve chemical modification of the mesh material by itself.
However, the deposition of hard-shell polymeric biomaterials over
the mesh knots and inter-filament spaces limits the filaments
mobility and ultimately impacts on the elastic behaviour of the
hybrid mesh [99]. Additionally, coating delamination during mesh
handling and implantation (for instance through laparoscopic
approach) could potentially lead to treatment failure and should be
systematically investigated, as shown Fig. 7D and E.
5.3. Chemical surface functionalization
Meshes functionalized by dipping/coating based technologies
are commonly characterized by a burst release profile of the drug
and a short-term period of antibacterial protection. In order to
circumvent such limitations, one option is to stabilize the thera-
peutic onto the surface of the mesh through not only physical but
chemical interactions. Such approaches have the advantages of not
dramatically impairing the mechanical behaviour of the mesh
substrate, as it i) does not involve chemical alteration of the bulk
material in the filament but only the superficial molecular layers, ii)
does not result in excessive agent deposition in the inter-filament
and knot spaces (no major modification of materials elasticity).
However, being able to graft bioactive compounds onto a mesh
substrate first requires the pre-activation of the surfaces, as the
main polymeric components of meshes are relatively inertFig. 7. Multi-layer coating on mesh using airbrush spray technology.
Illustration of the airbrush coating system allowing for the creation of a polymer reservoir e
mesh (A, B and C). Material delamination and deterioration resulting from cyclic elongation a
arrows respectively). Reprinted with permission from Refs. [93,99,124].chemically without reactive groups to be used as initiators for
further chemical functionalization (i.e. PP, PTFE, PET, PVDF, etc.). To
alleviate such restriction, several studies employed a plasma
treatment under controlled environmental condition (e.g. under
oxygen atmosphere) in order to trigger the formation of interme-
diate reactive species and functional groups [84,97,110,125]. Sub-
sequently, mesh activated by plasma treatment can either directly
enhance drug-surface interaction (i.e. meshes become more hy-
drophilic [97]), or be used as anchorage points to molecular teth-
ering (i.e. plasma-induced graft polymerization [84,101,110,125])
(Fig. 8A).
One first approach requires the chemical grafting of a polymeric
backbone spacer onto the mesh materials that will then serve as a
drug carrier. Using polymeric chain carriers alleviates the problem
of steric hindrance between the activated mesh and the drug and
the limited availability or accessibility of chemical groups, and
potentially increases the drug loading yield compared to a direct
drug-mesh grafting. Such optionwas developed by Junge et al., who
activated PVDF mesh material using plasma treatment in order to
create chemically active sites, which then allowed for acrylic acid
graft polymerization (polyacrylic acid (PAA)) from the PVDF surface
(Fig. 8A). Following the surface functionalization of the PVDF with
PAA, the antibiotic (e.g. gentamicin) was covalently immobilized on
the carboxylic acidic groups of the PAA pendent chains [84,95,125].
The stability of the antibiotic-PAA covalent interaction was directly
responsible for a limited burst effect (in vitro release of gentamicin
was 48% in 1 day and 73% in 7 days) and a potent inhibitory effect
on S. aureus growth after at least 24 h of incubation (reduction of
S. aureus concentration in suspension was above 99.9% [95],
Fig. 8B). Despite promising in vitro results, the antibacterial activity
of PVDF-PAA-Gentamicin to prevent infection in animal models has
not been made publicly available.
Indeed, covalent binding of anti-bacterial agents does not al-
ways correlate with a better efficacy, due to the restricted amount
of therapeutic released and made available for the bacteria. This
was also emphasized by Yurko et al., who observed that covalent
immobilization of antimicrobial peptides prevented its diffusion
from PP mesh, resulting in high bacterial survival rate compared to
a non-specific absorption approach [116].
As an alternative, nano-scale chemical coating surrounding the
prostheses can be created to act as an advanced drug reservoir,
increasing the physico-chemical interactions between the antibi-
otics and the substrate (Fig. 8C). For example, efficacy of ampicillin
loading to PP mesh was increased by a successive dual plasma
treatments of the PP fibres, aiming to 1- increase the interaction
drug-PP (via alteration of wettability, surface roughness, presence
of bonding sites), and 2- prevent cytotoxicity (by masking the drug
to eukaryote cells after entrapment within a PEG-grafted brush-like
matrix, Fig. 8D) [97]. This delivery strategy has shown benefices notntrapping antibacterial drugs (e.g. ofloxacin and rifampicin) around the filament of PP
ssay (the coating and the supportive PP materials are denoted with the white and black
Fig. 8. Illustration of the main strategies developed to covalently graft drug polymeric carriers on hernia meshes to confer antimicrobial protection.
Following plasma activation of the surface of meshes, macromolecular spacers can polymerize from the surfaces and be used as binding sites for further covalent immobilization of
antibiotics (A). This strategy does not alter mesh macroscopic features, while allowing for bacteria inhibition (after at least 24 h of incubation with S. aureus, B). Polymeric spacers
can also act as brushes increasing drug-mesh affinity (non-covalent interaction between polymers and the therapeutics, C). The coating brushes covering meshes can mask the
cytotoxic of the drug to fibroblasts (cells spreading onto mesh's surface are stained with crystal violet, D). Such strategy was not only successful for antibiotics, but also for silver
nanoparticles on PET meshes (against S. aureus and E. coli, as shown by the inhibition diameters compared to non-loaded PET (PPAA stands for Plasma Polymerized Polyacrylic Acid,
E). Macromolecular traps (i.e. cyclodextrin, CD) have been cross-linked surrounding the mesh filaments and loaded with hydrophobic drugs (F). The created CD molecules nano-
coating can be observed using SEM (G) and allowed to treat S. aureus infection on mice, to a better degree than non-treated and antibiotic flush groups (H). Reprinted with
permission from Refs. [84,87,91,95,97,110].
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Fig. 8E.
To further increase the adsorption property of mesh to targeted
therapeutics, several authors have incorporated macromolecular
traps in the chemical coating [86,87,91]. Cyclodextrins are cyclic
6e8 oligomers which exhibit the very advantage to have a hydro-
phobic cavity surrounded by hydrophilic corona containing active
chemical groups (hydroxyl), Fig. 8F. The hydrophobic core can take
up awide range of organic compounds, such as vancomycin [86,87]
or ciprofloxacin [91] and has shown promising efficacy as drug
delivery system in numerous field of application. The available
hydroxyl groups are usually employed as anchorage points for
cross-linkers, in order to stabilize the cyclodextrin (CD)-based as-
sembly in a chemical coating surrounding the mesh filaments.
Polyethylene glycol diglycidyl ether (PEGDGE) [87], citric acids [91]
or hexamethylene diisocyanate [86] are among the reported reac-
tive species to crosslink CD on the surface of polymer meshes.
Successful drug absorption of up to 42mg/g of CD-mesh (compared
to< 10mg/g for non-modified mesh) was reported by Laurent et al.
(Fig. 8G), which allowed for S. aureus and E. coli growth inhibition
for 24 h in vitro [91]. The available in vivo studies on mice (infected
dorsal subcutaneous pocket) revealed complete bacteria clearance
for groups treated with vancomycin-loaded meshes (bacteriolog-
ical inhibition significantly improved compared to native meshes
and to a local wound cleaning with an equivalent antibiotic flush
solution, Fig. 8H) [86,87].
6. New strategies to endow mesh with antibacterial
resistance
Among the alternatives to pharmaceutical drugs combined to
implants to endow anti-bacterial properties, surfaces tethered with
polycationic macromolecules have gained lots of interest. Positively
charged long-chain quaternary ammoniums are among the ones
with the greatest potential. Indeed, polyquaternary ammoniums(PQAs) can interact with the negatively charged membranes of
bacteria, inducing biocidal activity by cell lysis. Diverse synthetic
substrates have been functionalized using PQAs (such as PP [126],
PET [127], PVDF [128] and PLA [129]) showing in vitro efficacy
against a large number of bacteria (e.g. 99.999% of adhesion
reduction observed on modified PLA for E. coli, P. aeruginosa, S.
aureus and S. epidermidis [129]). Those preliminary investigations
offer great promise in the field of antimicrobial surfaces as they
confirm the relative non-specificity of PQAs and their bactericidal
activity against multi-drug resistant microorganisms. The only
available report on meshes (PP) coated with PQAs for infection
prophylaxis revealed that, even though no zone of inhibition was
observed surrounding the modified meshes, authors did observe a
significant reduction of bacteria adhesion (which was further
enhanced by loading the polymer with chlorhexidine) [123]. These
studies can bring clear advantages compared to the previous op-
tions (i.e. using antibiotics), but we have to keep in mind that such
antimicrobial surfaces i) do not entirely counterbalance risk of
resistance, as adaptation has already been reported on microor-
ganisms treated with quaternary ammonium based-biocides [130],
and ii) might be readily covered by proteins and subsequently by
fibrous tissue after their implantation in the body, decreasing their
bactericidal activity.
Creating anti-fouling implant surfaces which are either super-
hydrophilic (i.e. immobilizing PEG [131]) or super-hydrophobic
(i.e. dimethyldichlorosilane [132]) is another common approach
to decrease material colonization by infectious agents. Biomimetic
omniphobic surfaces (repelling both aqueous and organic liquids)
have been recently created by infusing microporous ePTFE allo-
plastic prostheses with several biocompatible fluorinated lubri-
cants (at 40 mL/cm2) [133]. The resulting SLIPS-ePTFE materials
(slippery liquid-infused porous surfaces) demonstrated in vitro S.
aureus adhesion reduction of approximately 2-log (compared to
non-coated ePTFE) after 48 h of incubation. In an infected rat
model, SLIPS-ePTFE resisted bacteria contamination 3 days post-
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attenuated peri-prosthetic inflammatory reaction and fibrosis for-
mation (capsule thickness reduced of 50% around SLIPS-ePTFE
compared to unmodified ePTFE). As the manipulation of the pros-
thesis with the SLIPS lubricant takes only few minutes, this process
could be applied by the surgical team just prior to the implantation,
which is a clearly more attractive and feasible technology than the
others detailed previously.
Alternatively, anti-infective delivery systems could be implan-
ted as adjunct devices to the main prosthesis to confer antibacterial
protection (Fig. 9). This approach has been successfully employed in
the field of orthopaedic and trauma surgery, where non-degradable
PMMA beads or resorbable collagen fleece loaded with gentamicin
are among the most popular products to prevent implant-related
infection (Fig. 9A) [48]. Musella et al. presented one clinical study
using similar bioactive collagen fleece placed in front of the mesh
[49]. Unfortunately, such practice has never reached a routine uti-
lization despite promising low rate of mesh-related sepsis (0.3%
versus 2.1% in control group). The local administration of anti-
infective delivery systems (adjacent to the prosthesis) through
minimal invasive route could bring benefices for some specific
abdominal wall surgeries (i.e. using laparoscopic approach). For
instance, the peri-prosthetic administration of vancomycin-
releasing microspheres (drug loading of ±10% w/w) was able to
prevent multifilament PE mesh infection (in mice model chal-
lenged with 104 S. aureus) [86] (Fig. 9B). Several “off-the-shelf"
vehicles have been developed as prophylaxis tool, for example in
bone surgery, using thermo-responsive hyaluronic derived hydro-
gel [134].
This system offers the advantage to be storable as a powder and
to be reconstituted as a liquid with the appropriate therapeutic(s)
just prior the surgery. Being a liquid at room temperature, the
surgeon can easily inject or administer the formulation at the sur-
gical site surrounding the prosthesis. Once placed within the
wound, the HA-pNIPAM forms a gel after reaching its LCST (LowerFig. 9. Degradable additive adjuvants to prostheses aiming to confer temporary protection
Antibiotic loaded collagen fleece applied at the surgical site before insertion of the implant (A
microspheres loaded with vancomycin (B) or thermoresponsive HA-pNIPAM (Poly(N-isopr
gelation (C). Reprinted with permission from Refs. [48,86,134].
Table 5
Reported clinical investigations available on anti-infective meshes in herniatology.
Treatment Company Patient
numbers
MycroMesh® Plus and DualMesh® Plus:
ePTFE patches impregnated with
chlorhexidine diacetate and
silver carbonate
GORE 18
DualMesh® Plus GORE 65
82
XenMatrix AB Surgical Graft:
Bioprosthesis with a coating
of rifampin/minocycline
BARD
Davol
74Critical Solution Temperature set at above± 25 C), allowing to
maintain in-situ the antibiotic and to control its diffusion (Fig. 9C).
In a rabbit model with contaminated bone fracture, such sol-gel
formulation loaded with gentamicin sulphate (at 1% w/v) offered
a total prevention of infection, showing that it could be as well of
great interest as adjunct to meshes in abdominal wall reconstruc-
tion [134]. Another hyaluronic acid-based medical device, DAC®
developed by Novagenit (http:/www.dac-coating.com/), recently
obtained the CE-marking. This biodegradable hydrogel formulation
can be loaded with antibiotic and be applied by the surgeon in the
theatre as coating to osteosynthesis implants to prevent SSI
[135,136]. Such strategy is versatile as it can be employed to coat
diverse implants, using diverse antibiotics as well. In addition, us-
ing bioactive adjuvants avoids the need to obtain the FDA-
authorization for every single type of mesh (in case of bioactive
mesh), but rather only for the adjuvant product. Such adjuvant
could also be used in herniorrhaphy, where no mesh is used to fix
the hernia defect, only suturing materials.
7. Commercially available products and clinical efficacy
Innovation in biomaterials and bioactive systems have paved
the way to the development and to the recent commercialization of
advanced meshes offering, among the activities, anti-infective
protection [124]. Few companies have succeeded in obtaining the
FDA clearance of antibiotic-loaded grafts (listed Table 5 and illus-
trated Fig. 10). The first antibiotic-loaded meshes were developed
by GORE (MycroMesh® Plus and DualMesh® Plus, Fig. 10A and B)
based on ePTFE patches impregnated with a synergistic chlorhex-
idine diacetate and silver carbonate mixture. As early as 1999, one
of the first reports regarding the reconstruction of hernia defects
with MycroMesh® Plus and DualMesh® Plus on patients was pub-
lished [137]. This short-term clinical study (on 37 patients with a
follow-up of 84 days post-operatively) aiming to investigate the
adverse effect of those bioactive patches rather than their real anti-against mesh-related infection.
). Example of local drug vehicle administrable through minimal invasive routes, such as
opylacrylamide) grafted hyaluronan) loaded with gentamicin formulation for in-situ
Outcomes Year of
publication
Ref.
No adverse effects and similar complications
compared to normal ePTFE
1999 [137]
No recorded infection but presence of
non-infectious post-operative fever
2005 [141]
Infection rates (5.8 up to 27.8%) significantly
higher than non ePTFE mesh ( ±2%)
2013 [28]
Within 30 days: 5 cases of re-infection
Within 6 months: 0 SSI, but 4 cases of
hernia recurrence, 3 cases of seroma and
3 of wound dehiscence
2016 [142]
Fig. 10. Antibiotic-eluting prostheses developed for hernia repair, FDA-cleared or under approval status.
GORE launched DualMesh® Plus and MycroMesh® Plus based of ePTFE impregnated with chlorhexidine diacetate and silver carbonate (A and B). Rifampin/minocycline coated
biological prosthesis (C) and synthetic mesh (D and E), developed by BARD (XenMatrix AB Surgical Graft, C and Ventrio™ Light Hernia Patch with TRM Antimicrobial Coating, E) or
Ariste Medical (D). Images A, B and D are available from suppliers' websites. C and E are reprinted with permission from Refs. [139,142].
O. Guillaume et al. / Biomaterials 167 (2018) 15e3128infective property, concluded to the safety of those products
(similar to non-drug loaded ePTFE), with an overall infection rate of
2.7%.
Then, more recently, the potential of those commercialized
patches to clear infection was screened on a contaminated animal
model (mice infected with S. aureus). It showed that Mycromesh®
Plus significantly diminished bacteria colonization of a 4-log unit
compared to competitive non-bioactive grafts [77]. Similar out-
comes were also obtained using inoculated rat model, where au-
thors observed that after 5 days of implantation, only the drugs-
loaded ePTFE patches could completely eradicate S. aureus (in 10
out of 12 specimens) [138]. Those pre-clinical results did not
corroborate with a more recent clinical retrospective review
focusing on infection prophylaxis using DualMesh® Plus, that did
not show any beneficial protection [28].
Since then, competitor BARD Davol has launched two different
hernia grafts endowed with antimicrobial properties. The 2012 FDA
cleared "Ventrio™ Light Hernia Patch with TRM Antimicrobial
Coating” is a composite mesh based on one-side macroporous PP
and anti-adhesive ePTFE on the second-side (designed to face the
viscera, Fig. 10E). The structure is coated with a degradable matrix
containing equal rifampicin/minocycline loading of 115 mg/cm2
each, embedded in a bioresorbable tyrosine-based polyarylate
polymeric matrix (called PIVIT A/B™ ST bioactive coating devel-
oped by TYRX Pharma). The few available data regarding its effi-
cacy, performed on a laparotomy rabbit model inoculated with
MRSA, demonstrated a significant decrease (compared to non-
bioactive grafts) or a complete eradication of bacteria (depending
on the initial inoculum concentration) [139].
Another prosthesis was FDA approved in 2014 from the same
company, based on a biological graft coated with similar dual-
antibiotics mixture (XenMatrix AB Surgical Graft, Fig. 10C). In a
rabbit model with subcutaneous implantation and inoculation of
MRSA or E. coli, no remnant bacteria could be isolated after 7 days
due to the local release of the therapeutics from the mesh [94].
Bacterial protection was supported by the slow and sustained
release of the incorporated drugs, as around 40% of active in-
gredients was still present on mesh materials after 5e7 days post-
implantation [94].
Last, but not the least, the first drug-eluting mesh made of only
macroporous polypropylene knitted filaments has been introduced
using Ariste Medical coating technology (with rifampin and min-
ocycline as active ingredients, Fig. 10D) with a FDA approval fore-
seen in the next month [140].
Nevertheless, the scarce amount of scientific reports publicly
available regarding those emerging technologies and products doesnot allow to draw any unanimous conclusions.
Further studies are warranted and needed to validate the utili-
zation of such bioactive infection-fighting meshes for high-risk
patient groups. Nevertheless, the authors are well aware that
such clinical studies dedicated to mesh infection prophylaxis or to
the treatment of established infection would be difficult to carry
out, as a large number of participants will be required to demon-
strate statistically significant advantages [17]. Only one clinical
study is under investigation on Cook® Antimicrobial Hernia Repair
Device, on 24 enrolled patients with first completion date planned
mid-2018 (study number NCT02401334).
8. Conclusion
The purpose of this review is to provide a broad vision of the
problem of mesh-related infection in abdominal wall reconstruc-
tion and to expose how the hernia community endeavours to
address it. From Deysine's 2004 provoking question “Are we doing
all we can?”, we can affirm that tremendous effort has been un-
dertaken from every actor in this field, from biomaterial scientists,
microbiologists up to clinicians. One must be aware that, to an
apparently minimal 1e4% risk of mesh-related infection in hernia
repairs, it does concretely correspond to several tens of thousands
of complicated clinical cases to treat annually. Advanced in anti-
infective biomaterial meshes is definitely one part of the solution
to prevent and/or to treat mesh sepsis, which is the principal focus
of this report. A huge variety of strategies are presented to confer
mesh protection against infection, using appropriate in vitro and
in vivo models. Such evolution is materialized by the recent FDA
approval of several options including meshes loaded with anti-
bacterial compounds, which might motivate and pave the way for
further exciting developments. In the authors' opinion, the main
challenges in the field of mesh-related infection are, i) to develop or
adopt a standardized animal model with infected hernia, ii) to
develop further analytic techniques allowing to better diagnose
dormant infection on patients presenting no sign of infection, iii) to
develop versatile antimicrobial adjuvants to meshes rather than
modified meshes (which will then require extensive Bioactive
Medical Device Regulatory authorization for every bioactive mesh
types), and finally iv-to be able to carry out larger clinical studies to
validate the utilization of bioactive mesh as prophylactic or as
treatment strategy.
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